Defining the Role of Icosapent Ethyl in Clinical Practice. [Review]

MedStar author(s):
Citation: American Journal of Cardiovascular Drugs. 20(6):517-524, 2020 Dec.PMID: 32157567Institution: MedStar Union Memorial HospitalForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Eicosapentaenoic Acid/aa [Analogs & Derivatives] | *Hypertriglyceridemia/dt [Drug Therapy] | Drug Dosage Calculations | Eicosapentaenoic Acid/ad [Administration & Dosage] | Eicosapentaenoic Acid/ae [Adverse Effects] | Eicosapentaenoic Acid/tu [Therapeutic Use] | Humans | Randomized Controlled Trials as Topic | Risk FactorsYear: 2020Local holdings: Available online from MWHC library: 2001 - 2009ISSN:
  • 1175-3277
Name of journal: American journal of cardiovascular drugs : drugs, devices, and other interventionsAbstract: The health benefit of fish oil, i.e. omega-3 fatty acids (omega-3 FA) has a long history of debate. While there are a number of medications to reduce serum triglyceride levels, none have shown unanimous cardiovascular (CV) benefits. The most recent Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) assessing the CV outcome of one highly purified prescription omega-3 FA has certainly rejuvenated the debate. While this trial has been regarded as one of the most important landmark trials in preventive cardiology, the tolerability issue in a very high dose (4 g/day, as administered in the trial) is still a matter of concern. This article summarizes the current status and future perspective of icosapent ethyl in clinical practice in light of REDUCE-IT.All authors: Bandyopadhyay D, Chatterjee S, Deedwania PC, Ghosh RK, Hajra AOriginally published: American Journal of Cardiovascular Drugs. 2020 Mar 11Fiscal year: FY2021Fiscal year of original publication: FY2020Digital Object Identifier: Date added to catalog: 2020-07-09
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 32157567 Available 32157567

Available online from MWHC library: 2001 - 2009

The health benefit of fish oil, i.e. omega-3 fatty acids (omega-3 FA) has a long history of debate. While there are a number of medications to reduce serum triglyceride levels, none have shown unanimous cardiovascular (CV) benefits. The most recent Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) assessing the CV outcome of one highly purified prescription omega-3 FA has certainly rejuvenated the debate. While this trial has been regarded as one of the most important landmark trials in preventive cardiology, the tolerability issue in a very high dose (4 g/day, as administered in the trial) is still a matter of concern. This article summarizes the current status and future perspective of icosapent ethyl in clinical practice in light of REDUCE-IT.

English

Powered by Koha